Belvedere Trading
RAPP

Belvedere Trading’s Rapport Therapeutics RAPP Stock Holding History

Belvedere Trading’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-300
Closed -$8.91K – 1140
2025
Q3 		$8.91K Buy
+300
New +$5.35K ﹤0.01% 804

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Belvedere Trading's RAPP Position: Q4 2025 in Review

Belvedere Trading sold out of Rapport Therapeutics (RAPP) in Q4 2025, closing a stake of 3,728 shares — an estimated $111K sold.

Belvedere Trading first reported a position in RAPP in Q3 2025 and held it in 1 quarter. The position peaked at $111K in Q3 2025. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Belvedere Trading reported no remaining Rapport Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Belvedere Trading sold 3,728 Rapport Therapeutics shares in Q4 2025, an estimated $111K.
  • Belvedere Trading first reported a position in Rapport Therapeutics in Q3 2025 and held it in 1 quarter.
  • Belvedere Trading's Rapport Therapeutics position peaked at $111K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Belvedere Trading's 13F filing for Q4 2025, filed 10 Feb 2026.